-
公开(公告)号:US20140142032A1
公开(公告)日:2014-05-22
申请号:US13724266
申请日:2012-12-21
申请人: Zhi-Qiang Jiang , Arunya Usayapant , David Bowman , Keith Kwok , Joel Peterson
发明人: Zhi-Qiang Jiang , Arunya Usayapant , David Bowman , Keith Kwok , Joel Peterson
IPC分类号: A61K38/12
CPC分类号: A61K47/183 , A61K9/0019 , A61K9/19 , A61K31/198 , A61K38/12 , A61K2300/00
摘要: A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture.
摘要翻译: 卡泊芬净组合物包括乙酸卡泊芬净和至少一种氨基酸,其中组合物是固体。 固体组合物可以通过形成包括溶剂,乙酸卡泊芬净和氨基酸的液体混合物,并将液体混合物冻干来制备。
-
公开(公告)号:US09006289B2
公开(公告)日:2015-04-14
申请号:US13597884
申请日:2012-08-29
申请人: Zhi-Qiang Jiang , Arunya Usayapant , George Monen
发明人: Zhi-Qiang Jiang , Arunya Usayapant , George Monen
IPC分类号: A61K31/198 , A61K47/26 , A61K9/00 , A61K9/19
CPC分类号: A61K9/19 , A61K9/0019 , A61K31/197 , A61K31/198 , A61K47/02 , A61K47/10 , A61K47/26
摘要: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40:1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10:1.
摘要翻译: 左甲状腺素组合物包括左甲状腺素钠和甘露糖醇。 组合物是固体。 该组合物可以包含100至500微克左旋甲状腺素钠和1至5毫克甘露醇。 组合物可以包含100至200微克左甲状腺素钠,组合物中甘露醇与左甲状腺素钠的质量比可以至多为40:1。 组合物可以包含约500微克左甲状腺素钠,组合物中甘露醇与左甲状腺素钠的质量比可以至多为10:1。
-
公开(公告)号:US20130053445A1
公开(公告)日:2013-02-28
申请号:US13597884
申请日:2012-08-29
申请人: Zhi-Qiang Jiang , Arunya Usayapant , George Monen
发明人: Zhi-Qiang Jiang , Arunya Usayapant , George Monen
IPC分类号: A61K31/198
CPC分类号: A61K9/19 , A61K9/0019 , A61K31/197 , A61K31/198 , A61K47/02 , A61K47/10 , A61K47/26
摘要: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40:1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10:1.
摘要翻译: 左甲状腺素组合物包括左甲状腺素钠和甘露糖醇。 组合物是固体。 该组合物可以包含100至500微克左旋甲状腺素钠和1至5毫克甘露醇。 组合物可以包含100至200微克左甲状腺素钠,组合物中甘露糖醇与左甲状腺素钠的质量比可以至多为40:1。 组合物可以包含约500微克左甲状腺素钠,组合物中甘露醇与左甲状腺素钠的质量比可以至多为10:1。
-
公开(公告)号:US20120083457A1
公开(公告)日:2012-04-05
申请号:US13252421
申请日:2011-10-04
申请人: Arunya Usayapant , David Bowman
发明人: Arunya Usayapant , David Bowman
IPC分类号: A61K38/05
CPC分类号: A61K31/69 , A61K9/0019 , A61K9/19 , A61K33/22 , A61K2300/00
摘要: A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture.
摘要翻译: 硼替佐米组合物包括硼替佐米和硼酸,硼酸与硼替佐米的质量比为1:1至10:1。 该组合物是固体,并且可以通过形成包含溶剂,硼替佐米和硼酸的液体混合物并且将液体混合物冻干来制备。
-
公开(公告)号:US09636407B2
公开(公告)日:2017-05-02
申请号:US13724266
申请日:2012-12-21
IPC分类号: A61K31/198 , A61K47/18 , A61K38/12 , A61K9/19 , A61K9/00
CPC分类号: A61K47/183 , A61K9/0019 , A61K9/19 , A61K31/198 , A61K38/12 , A61K2300/00
摘要: A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture.
-
公开(公告)号:US08962572B2
公开(公告)日:2015-02-24
申请号:US13252421
申请日:2011-10-04
申请人: Arunya Usayapant , David Bowman
发明人: Arunya Usayapant , David Bowman
CPC分类号: A61K31/69 , A61K9/0019 , A61K9/19 , A61K33/22 , A61K2300/00
摘要: A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture.
摘要翻译: 硼替佐米组合物包括硼替佐米和硼酸,硼酸与硼替佐米的质量比为1:1至10:1。 该组合物是固体,并且可以通过形成包含溶剂,硼替佐米和硼酸的液体混合物并且将液体混合物冻干来制备。
-
公开(公告)号:US20080118570A1
公开(公告)日:2008-05-22
申请号:US11561723
申请日:2006-11-20
申请人: Zhi Liu , Bei Chen , Danchen Gao , Mukti S. Rao , Arunya Usayapant
发明人: Zhi Liu , Bei Chen , Danchen Gao , Mukti S. Rao , Arunya Usayapant
IPC分类号: A61K9/16 , A61K47/48 , A61K31/439 , A61K31/216 , A61K31/4355 , A61K31/137
CPC分类号: A61K31/137 , A61K9/0095 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K31/216 , A61K31/4355 , A61K31/439 , A61K47/585 , A61K47/60 , A61K47/6921
摘要: Included are compositions, and methods of making, coated controlled-release drug and ion exchange resin form complexes. Methacrylate coatings, which can be free of plasticizers particularly with Eudragit® NE type polymer, are preferred to enhance the control of drug release from the drug-resin complexes. Liquid formulations including the coated resin forms and a chelating agent to inhibit degradation are also included.
摘要翻译: 包括组合物和制备方法,包被的控释药物和离子交换树脂形成复合物。 优选不含增塑剂的甲基丙烯酸酯涂料,尤其是用于NE型聚合物,以增强药物 - 树脂复合物的药物释放控制。 还包括包含涂覆的树脂形式的液体制剂和抑制降解的螯合剂。
-
-
-
-
-
-